US Representative

David Rouzer 2023-2024 Regular Session - Authored & Sponsored Legislation (Page 8)

Legislative Session

Co-Sponsor of Legislation

US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3887

Introduced
6/7/23  
Refer
6/7/23  
Refer
6/9/23  
Children’s Hospital GME Support Reauthorization Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3972

Introduced
6/9/23  
Refer
6/9/23  
Flood Resiliency and Land Stewardship Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4070

Introduced
6/13/23  
Disaster Mitigation and Tax Parity Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4076

Introduced
6/13/23  
Refer
6/13/23  
United States-Israel Health Technologies Cooperation Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4103

Introduced
6/14/23  
Refer
6/14/23  
Ensuring Fee-Free Benefit Transactions Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4127

Introduced
6/14/23  
Refer
6/14/23  
Fair Access to Agriculture Disaster Programs Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4148

Introduced
6/15/23  
Import Security and Fairness Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4167

Introduced
6/15/23  
Refer
6/15/23  
Refer
6/16/23  
Protecting America’s Distribution Transformer Supply Chain Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4175

Introduced
6/15/23  
Refer
6/15/23  
REPO for Ukrainians Act Rebuilding Economic Prosperity and Opportunity for Ukrainians Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4237

Introduced
6/21/23  
Ensuring Sound Guidance Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4245

Introduced
6/21/23  
Enforce the Caps Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB425

Introduced
1/20/23  
History and Tradition Protection Act of 2023 This bill limits the types of relief that may be awarded in civil suits that involve violations of the Constitution's Establishment Clause, which prohibits the government from establishing a religion. Current law provides a statutory civil cause of action against state and local government actors for violations of constitutional rights, also known as Section 1983 lawsuits. The bill limits relief for Section 1983 lawsuits that involve violations of the Establishment Clause to injunctive and declaratory relief (i.e., nonmonetary relief) and prohibits the award of attorneys' fees in these cases, including those that involve monuments, public buildings, official seals, and government proceedings. The bill applies the same restrictions to similar lawsuits against federal agencies.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB427

Introduced
1/20/23  
Refer
1/20/23  
Support And Value Expectant Moms and Babies Act of 2023 or the SAVE Moms and Babies Act of 2023 This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved. Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner. The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner from also acting as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient. The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4278

Introduced
6/22/23  
Refer
6/22/23  
Refer
7/10/23  
Restore VA Accountability Act of 2023 Restore Department of Veterans Affairs Accountability Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4293

Introduced
6/22/23  
American Farmers Feed the World Act of 2023